CSPC Innovation (300765.SZ): SYS6010 included in the breakthrough therapy designation list for the treatment of patients with driver gene-negative non-squamous non-small cell lung cancer

Zhito Finance APP News: CSPC Innovation (300765.SZ) announced that SYS6010, developed by its controlling subsidiary CSPC Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Biopharmaceutical"), has been included in the breakthrough therapy designation list by the Center for Drug Evaluation (hereinafter referred to as "CDE") of the National Medical Products Administration.